Results 31 to 40 of about 233,497 (306)

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display

open access: yesJournal of Translational Medicine, 2023
Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji   +2 more
doaj   +1 more source

Plasmodium falciparum antigens on the surface of the gametocyte-infected erythrocyte. [PDF]

open access: yes, 2008
BACKGROUND: The asexual blood stages of the human malaria parasite Plasmodium falciparum produce highly immunogenic polymorphic antigens that are expressed on the surface of the host cell.
Christopher J. Drakeley   +26 more
core   +2 more sources

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

open access: yesFrontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. [PDF]

open access: yes, 2011
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL).
Graham P. Collins   +34 more
core   +2 more sources

Differential recognition patterns of Schistosoma haematobium adult worm antigens by the human antibodies IgA, IgE, IgG1 and IgG4 [PDF]

open access: yes, 2010
Schistosoma haematobium antigen recognition profiles of the human isotypes IgA, IgE, IgG1 and IgG4 were compared by image analysis of western blots. Adult worm antigens separated by 2-dimensional gel electrophoresis were probed with pooled sera from ...
Midzi, N.   +28 more
core   +1 more source

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

open access: yesPLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn   +6 more
doaj   +2 more sources

Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates [PDF]

open access: yes, 2023
Antibody-drug conjugates consist of potent small molecule payloads linked to a targeting antibody. Payloads must possess a viable functional group by which a linker for conjugation can be attached.
Axel, Hernandez, Jr.   +12 more
core   +2 more sources

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

open access: yesJournal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung   +6 more
doaj   +1 more source

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

open access: yesFrontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu   +3 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy